; The mission of the MSCP SPORE Career Development Program (CDP) is to stimulate basic, translational, and clinical research by recruiting and supporting new investigators in the area of melanoma and other skin cancers. The CDP provides financial resources for this mission, while the SPORE itself provides a supportive and stimulating research environment. In the previous MSCP SPORE grant period, we supported 7 CDP awardees, all but one of whom were eariy-stage investigators (one Research Associate, one Research Instructor, and four Assistant or Research Assistant Professors);5 of our 7 CDP awardees were women. All CDP Awardees have experienced success in advancing their careers, publishing their work, and obtaining extramural funding. We will continue to solicit proposals twice per year and to use a peer-reviewed scoring system to prioritize proposals for funding. The CDP Co-Directors, Executive Committee, and Internal and External Advisory Board members participate in the review process, together with the Patient Advocates and additional experts who may be called upon if special reviewer expertise is necessary. The CDP will track progress of the successful applications and provide advisors to funded investigators to ensure that they obtain any needed services from the MSCP SPORE Cores (Administrative Core A;Biospecimen Core B;Biostatistics Core C;and Informatics Core D) and that they are integrated into the SPORE program. Awardees present their research results to the SPORE investigators after one year of support to be eligible for a second year of support. Progress toward translation as well as impact and innovation will determine whether CDP projects are found to merit promotion to full SPORE projects. Awardees will also be advised as appropriate in the preparation of grant applications for funding outside the SPORE mechanism and given access to Core resources to aid in this endeavor.
The MSCP SPORE will identify and support investigators new to research in melanoma and skin cancer with both pilot study funding and expertise and assistance in planning and preparing grant applications for independent funding.
|Anderson, Alyce; Ferris, Laura K; Click, Benjamin et al. (2018) Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci 63:2729-2739|
|Zhang, Yi; Liu, Zuqiang; Hao, Xingxing et al. (2018) Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model. Cancer Immunol Immunother 67:353-366|
|Lemchak, David; Banerjee, Swati; Digambar, Shaunak S et al. (2018) Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Exp Dermatol 27:188-190|
|Matsumoto, Martha; Secrest, Aaron; Anderson, Alyce et al. (2018) Estimating the cost of skin cancer detection by dermatology providers in a large health care system. J Am Acad Dermatol 78:701-709.e1|
|Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054|
|Santos, Patricia M; Butterfield, Lisa H (2018) Dendritic Cell-Based Cancer Vaccines. J Immunol 200:443-449|
|Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :|
|Retseck, Janet; Nasr, Alexis; Lin, Yan et al. (2018) Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. J Transl Med 16:184|
|Velásquez, Celestino; Amako, Yutaka; Harold, Alexis et al. (2018) Characterization of a Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Line CVG-1. Front Microbiol 9:713|
|Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15|
Showing the most recent 10 out of 209 publications